期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 122, 期 6, 页码 1973-1990出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI61495
关键词
-
资金
- NIH [HL091076, HL115141, F32HL088819]
- American Cancer Society [RSG0719501-LIB]
- Boston Area Diabetes Endocrinology Research Center [P30DK057521]
- Watkins Cardiovascular Medicine Discovery Award
EC activation and dysfunction have been linked to a variety of vascular inflammatory disease states. The function of microRNAs (miRNAs) in vascular EC activation and inflammation remains poorly understood. Herein, we report that microRNA-181b (miR-181b) serves as a potent regulator of downstream NF-kappa B signaling in the vascular endothelium by targeting importin-alpha 3, a protein that is required for nuclear translocation of NF-kappa B. Overexpression of miR-181b inhibited importin-alpha 3 expression and an enriched set of NF-kappa B-responsive genes such as adhesion molecules VCAM-1 and E-selectin in ECs in vitro and in vivo. In addition, treatment of mice with proinflammatory stimuli reduced miR-181b expression. Rescue of miR-181b levels by systemic administration of miR-181b mimics reduced downstream NF-kappa B signaling and leukocyte influx in the vascular endothelium and decreased lung injury and mortality in endotoxemic mice. In contrast, miR-181b inhibition exacerbated endotoxin-induced NF-kappa B activity, leukocyte influx, and lung injury. Finally, we observed that critically ill patients with sepsis had reduced levels of miR-181b compared with control intensive care unit (ICU) subjects. Collectively, these findings demonstrate that miR-181b regulates NF-kappa B-mediated EC activation and vascular inflammation in response to proinflammatory stimuli and that rescue of miR-181b expression could provide a new target for antiinflammatory therapy and critical illness.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据